Status:
COMPLETED
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam
Lead Sponsor:
UCB Pharma
Conditions:
Epilepsy
Eligibility:
All Genders
16+ years
Phase:
PHASE3
Brief Summary
The Sponsor wishes to develop brivaracetam as an anti-epileptic treatment in subjects 16 years and older with epilepsy. This study permits continued access to treatment for subjects who participated i...
Eligibility Criteria
Inclusion
- Subjects with epilepsy who participated in previous brivaracetam trials which allow access to the present trial.
- Subjects from whom the Investigator believes a reasonable potential benefit from the long-term administration of brivaracetam may be expected.
Exclusion
- • Severe medical, neurological and psychiatric disorders, including current suicidal ideation or behaviour, or laboratory values which may have an impact on the safety of the subject, as determined by the investigator.
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2017
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT00761774
Start Date
November 1 2008
End Date
March 1 2017
Last Update
July 11 2018
Active Locations (58)
Enter a location and click search to find clinical trials sorted by distance.
1
304
Phoenix, Arizona, United States
2
281
Fresno, California, United States
3
288
Pasadena, California, United States
4
240
Riverside, California, United States